Corrigendum: A personalized approach to treatment: use of egfr tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada

Ähnliche Einträge

• A personalized approach to treatment: use of egfr tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada
  von: Hirsh, V., et al.
  Veröffentlicht: (2012)
• egfr tyrosine kinase inhibitors in lung cancer: make no assumptions
  von: Melosky†, B.
  Veröffentlicht: (2012)
• Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer
  von: Hirsh, V.
  Veröffentlicht: (2011)
• Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
  von: Hirsh, Vera
  Veröffentlicht: (2018)
• Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
  von: Xu, Jianlin, et al.
  Veröffentlicht: (2016)